Ingrid A
Chairman of the Board
San Miguel Corporation
Norway
Biography
Dr. Ingrid Alfheim is CEO of Bio-Medisinsk Innovasjon AS, a company that commercializes spin-offs from the university hospitals in the Oslo region. She has more than 20 years experience in basic and applied research within chemistry, biochemistry, toxicology and biotechnology. She held the position as CSO of a biotech start-up company Euromed AS and director of R&D in the Scottish Norwegian diagnostic company Axis-Shield (1996-2004), where she was heading research groups in Norway, Scotland and in the US. She has been a board member of several biotech start-ups, including Diagenic ASA now on the Norwegian stock exchange and has for 8 years been a board member of the Science Foundation at Radiumhospitalet. She has been a board member of several public research institutes, the Research Council of Norway in charge of the pan European research programme Eureka and is currently a board member of the Norwegian Bioindustry Association and of the Biotec Pharmacon ASA.
Research Interest
Dr. Ingrid Alfheim is CEO of Bio-Medisinsk Innovasjon AS, a company that commercializes spin-offs from the university hospitals in the Oslo region. She has more than 20 years experience in basic and applied research within chemistry, biochemistry, toxicology and biotechnology. She held the position as CSO of a biotech start-up company Euromed AS and director of R&D in the Scottish Norwegian diagnostic company Axis-Shield (1996-2004), where she was heading research groups in Norway, Scotland and in the US. She has been a board member of several biotech start-ups, including Diagenic ASA now on the Norwegian stock exchange and has for 8 years been a board member of the Science Foundation at Radiumhospitalet. She has been a board member of several public research institutes, the Research Council of Norway in charge of the pan European research programme Eureka and is currently a board member of the Norwegian Bioindustry Association and of the Biotec Pharmacon ASA.
